HYPERTENSION RESEARCH, published by SpringerNature, serves as a premier platform in the field of Cardiology and Cardiovascular Medicine, Internal Medicine, and Physiology. Since its inception in 1992, the journal has built a substantial reputation, currently ranked in the second quartile (Q2) across several categories in 2023, reflecting its influence and high-quality contributions to medical research. With a focus on hypertension, the journal aims to disseminate vital research findings, clinical studies, and innovative treatment strategies to a diverse audience of researchers, healthcare professionals, and students, fostering knowledge exchange in the management of hypertensive conditions. Although it is not an Open Access journal, it offers comprehensive access to its extensive archive of valuable resources, ensuring that critical advancements in the understanding of hypertension are both accessible and impactful. HYPERTENSION RESEARCH is not only essential for those directly involved in cardiovascular and internal medicine practices but also for interdisciplinary scholars who are looking to explore the intersections of physiology and other biomedical fields in their work.

Journal fur Hypertonie is a leading academic journal published by KRAUSE & PACHERNEGG GMBH, dedicated to the critical field of hypertension research. Since its inception in 1998, the journal has served as a vital platform for disseminating pioneering studies and advancements in the diagnosis, treatment, and management of hypertension. Although its Scopus coverage was discontinued in 2016, the journal continues to hold significance within the academic community, evidenced by its ranking of #98 out of 124 in Internal Medicine, placing it in the 21st percentile. This reflects its targeted impact and relevance in the evolving landscape of cardiovascular research. With no Open Access options, the journal remains a specialized resource indispensable for researchers, healthcare professionals, and students focused on enhancing their understanding and clinical practices related to hypertension. The journal's address is MOZARTGASSE 10, GABLITZ 3003, AUSTRIA.

Diabetes & Metabolism Journal, published by the Korean Diabetes Association, is a leading open-access journal dedicated to advancing the field of endocrinology, with a specific focus on diabetes and metabolism. Since its establishment in 1991, the journal has provided a robust platform for disseminating high-quality research, contributing significantly to our understanding of diabetes pathophysiology, treatment, and prevention strategies. The journal boasts an impressive impact factor, ranking in the top quartile (Q1) of its category and occupying the 28th position out of 244 in Scopus rankings, which places it in the 88th percentile among its peers. With its commitment to open access, researchers, professionals, and students globally can explore the latest findings and innovative solutions in diabetes research. The journal continues to serve as an essential resource for those dedicated to improving patient outcomes and advancing scientific knowledge in the metabolic disorders domain.

HYPERTENSION IN PREGNANCY is a leading academic journal dedicated to the critical study of hypertensive disorders during pregnancy, a crucial area of maternal and fetal health. Published by Taylor & Francis Inc, this journal boasts an Open Access policy since 2023, ensuring that research findings are freely accessible to a global audience. With an ISSN of 1064-1955 and E-ISSN of 1525-6065, it offers a platform for high-quality research and review articles since its inception in 1982. The journal holds a Q3 category ranking in both Internal Medicine and Obstetrics and Gynecology, reflecting its reputable standing within the scientific community. As of 2023, it ranks among the top quartile publications in its field, with Scopus ranking it 86/209 in Obstetrics and Gynecology and 83/167 in Internal Medicine. This journal aims to foster dialogue among researchers, clinicians, and policymakers regarding the management and implications of hypertension in pregnancy, promoting advancements in care and research methodologies. Located in Philadelphia, PA, it continues to be an invaluable resource for those invested in improving maternal health outcomes and advancing the field.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Pregnancy Hypertension – An International Journal of Women's Cardiovascular Health, published by Elsevier Science Ltd, is a leading platform dedicated to advancing the understanding of cardiovascular health in women during pregnancy and postpartum periods. With an ISSN of 2210-7789, this esteemed journal has distinguished itself in the fields of Internal Medicine and Obstetrics and Gynecology, maintaining a remarkable Q2 ranking in Internal Medicine and a prestigious Q1 ranking in Obstetrics and Gynecology as of 2023. It is recognized for its high-quality research, which fits within the top quartile of its categories, and spans from 2010 to 2024, reflecting its ongoing contribution to critical advancements in women's cardiovascular health. The journal is accessible to a global audience of researchers, practitioners, and students, emphasizing its commitment to promoting open scholarly communication, although it currently operates under traditional access. The publication serves as a crucial resource for those seeking to enhance their knowledge and practices related to the unique cardiovascular challenges faced by women during pregnancy, thereby fostering informed clinical approaches and improved health outcomes.

CURRENT DIABETES REVIEWS is a leading academic journal published by Bentham Science Publishers Ltd, dedicated to disseminating high-quality reviews and cutting-edge insights in the field of Endocrinology, Diabetes and Metabolism. Established in 1996 and actively publishing from 2005 to 2024, this journal holds a prestigious position within the academic community, evidenced by its Q2 ranking in both relevant categories for 2023 and its impactful presence in Scopus, where it ranks #83 out of 244 in Endocrinology and Diabetes and Metabolism. Despite being a subscription-based journal, it provides researchers, healthcare professionals, and students with valuable contributions that significantly advance the understanding of diabetes and related metabolic disorders. With a commitment to promoting interdisciplinary collaboration and innovation, CURRENT DIABETES REVIEWS serves as an essential resource for those seeking to stay abreast of the latest developments in diabetes research and therapies.

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.